• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 20, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Reduced-dose gadobutrol vs standard-dose gadoterate for contrast-enhanced brain MRI

Bioengineer by Bioengineer
September 6, 2025
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus 100%-standard dose of gadoterate for contrast-enhanced brain MRI, particularly in patients undergoing multiple contrast-enhanced examinations

Leesburg, VA, June 17, 2021–According to ARRS’ American Journal of Roentgenology (AJR), a reduced dose of gadobutrol is non-inferior to 100%-standard dose of gadoterate for contrast-enhanced brain MRI.

“A 25% reduced gadobutrol dose demonstrated non-inferior efficacy versus standard dose gadoterate for contrast-enhanced brain MRI,” corresponding author Jan Endrikat of Germany’s University Medical School of Saarland elaborated, “warranting particular consideration in patients undergoing multiple contrast-enhanced examinations.”

In this international, prospective, multicenter, open-label, crossover trial (LEADER-75), 141 patients (78 men, 63 women; mean age, 58.5 years) with known or suspected CNS pathology underwent contrast-enhanced brain MRI with standard-dose gadoterate (0.1 mmol/ kg). If an enhancing lesion was identified, a second MRI with reduced-dose gadobutrol (0.075 mmol/kg) was performed within 15 days.

Comparison of reduced-dose gadobutrol and standard-dose gadoterate versus unenhanced imaging demonstrated noninferiority using 20% margin for three primary efficacy measures: subjective lesion enhancement, lesion border delineation, lesion internal morphology.

Furthermore, in post-hoc analysis, mean readings for subjective lesion enhancement, lesion border delineation, and lesion internal morphology differed by less than 1%–supporting equivalence using a narrow ±5% margin.

“Various secondary variables also supported non-inferiority of reduced-dose gadobutrol,” the authors of the AJR article added.

###

Founded in 1900, the American Roentgen Ray Society (ARRS) is the first and oldest radiological society in North America, dedicated to the advancement of medicine through the profession of radiology and its allied sciences. An international forum for progress in medical imaging since the discovery of the x-ray, ARRS maintains its mission of improving health through a community committed to advancing knowledge and skills with an annual scientific meeting, monthly publication of the peer-reviewed American Journal of Roentgenology (AJR), quarterly issues of InPractice magazine, AJR Live Webinars and Podcasts, topical symposia, print and online educational materials, as well as awarding scholarships via The Roentgen Fund®.

Media Contact
Logan K. Young
[email protected]

Original Source

https://arrs.org/ARRSLIVE/Pressroom/PressReleases/Reduced_Gadobutrol_vs_Standard_Gadoterate_Contrast-Enhanced_Brain_MRI.aspx

Related Journal Article

http://dx.doi.org/10.2214/AJR.21.25924

Tags: Clinical TrialsDiagnosticsHealth Care Systems/ServicesMedicine/HealthneurobiologyNeurochemistryPharmaceutical ChemistryPharmaceutical Science
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Innovative Protective Coating for Spacecraft in Development by Engineers

October 20, 2025
blank

Scientists Uncover Life’s Building Blocks in Ice Surrounding a Forming Star in Nearby Galaxy

October 20, 2025

Copper-Catalyzed Asymmetric Cross-Coupling with Reactive Radicals

October 20, 2025

The Quantum Doorway Puzzle: Electrons Struggling to Find Their Exit

October 20, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1267 shares
    Share 506 Tweet 316
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    301 shares
    Share 120 Tweet 75
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    129 shares
    Share 52 Tweet 32
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    112 shares
    Share 45 Tweet 28

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Dimethyl Fumarate Boosts Antitumor Immunity in Cervical Cancer

Museum Genomic Research Reveals Pathogens Not Responsible for Franklin’s Bumble Bee Population Decline

Soil Amendments Boost Wheat Yields in Namibia

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 65 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.